New Data at AACR Meeting Highlights DecisionDx-Melanoma
Castle Biosciences presented new research on cutaneous and uveal melanoma (CM and UM) at the 2025 American Association for...
Myriad Genetics Presents MRD Data at AACR Meeting
Myriad Genetics presented clinical data at the American Association for Cancer Research (AACR) Annual Meeting showcasing the performance of...
Promising Preclinical Results for Micvotabart Pelidotin
Pyxis Oncology revealed promising preclinical data for its lead antibody-drug conjugate, micvotabart pelidotin (MICVO), at the 2025 American Association...
Evorpacept Shows Encouraging Results in B-Cell Lymphoma Trial
ALX Oncology’s investigational CD47-blocker, evorpacept, combined with rituximab and lenalidomide (R2), showed promising results in a Phase 1/2 trial...
Starton Therapeutics STAR-LLD Shows Promise in Multiple Myeloma Phase 1b Study
Starton Therapeutics presented positive Phase 1b data for STAR-LLD, a continuous low-dose lenalidomide therapy for relapsed/refractory multiple myeloma (MM),...
Olema Oncology Reveals New Preclinical Data for OP-3136 at AACR 2025
Olema Pharmaceuticals announced preclinical data for OP-3136, a KAT6 inhibitor, showing anti-tumor activity in ovarian, prostate, and non-small cell...
Harbinger Health Unveils Promising Cancer Detection Data
Harbinger Health presented new research at the American Association for Cancer Research (AACR) Annual Meeting showcasing advancements in their...
Zenflow Spring System: 3-Year Data Shows Durability of Clinical Benefits for BPH Patients
Zenflow, Inc. released three-year data from its ZEST pilot studies, demonstrating sustained positive outcomes for patients using the Zenflow...
Johnson & Johnson’s Tar-200 Achieves High Disease-Free Survival
Janssen-Cilag International NV announced promising interim results from the Phase 2b SunRISe-1 study (Cohort 4) of TAR-200, a gemcitabine-releasing...
ProTara Therapeutics Announces Positive Interim Results from Phase 2 Advanced-2 Trial of Tara-002 in Patients with NMIBC
Protara Therapeutics announced updated Phase 2 trial results for TARA-002, a cell-based therapy for Non-Muscle Invasive Bladder Cancer (NMIBC)....